Targeting classical complement pathway to treat complement mediated autoimmune diseases

Erdem Tüzün, Jing Li, Shamsher S. Saini, Huan Yang, Premkumar Christadoss

Research output: Chapter in Book/Report/Conference proceedingChapter

12 Citations (Scopus)

Abstract

Mice deficient for classical complement pathway (CCP) factor C4 are resistant to antibody and complement mediated experimental autoimmune myasthenia gravis (EAMG). Anti-C1q antibody administration before or following acetylcholine receptor immunization suppresses EAMG development by reducing lymph node cell IL-6 production and neuromuscular junction IgG, C3 and C5b-C9 deposition. This effect is achieved by treating mice with 10 μg of anti-C1q antibody, twice weekly for 4 weeks. Treatment with a higher amount of anti-C1q antibody gives rise to increased serum anti-acetylcholine receptor antibody, immune complex and C3 levels, facilitates kidney C3 and IgG deposits and thus reduces the treatment efficacy. C4 KO and anti-C1q antibody treated mice display normal immune system functions and intact antibody production capacity. Furthermore, CCP inhibition preserves alternative complement pathway activation, which is required for host defense against microorganisms. Therefore, CCP inhibition might constitute a specific treatment approach for not only myasthenia gravis but also other complement mediated autoimmune diseases.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
Pages265-272
Number of pages8
Volume632
StatePublished - 2008

Publication series

NameAdvances in Experimental Medicine and Biology
Volume632
ISSN (Print)00652598

Fingerprint

Classical Complement Pathway
Autoimmune Diseases
Anti-Idiotypic Antibodies
Autoimmune Experimental Myasthenia Gravis
Antibodies
Cholinergic Receptors
Immunoglobulin G
Alternative Complement Pathway
Neuromuscular Junction
Myasthenia Gravis
Antigen-Antibody Complex
Antibody Formation
Immune System
Immunization
Interleukin-6
Lymph Nodes
Kidney
Immune system
Microorganisms
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Tüzün, E., Li, J., Saini, S. S., Yang, H., & Christadoss, P. (2008). Targeting classical complement pathway to treat complement mediated autoimmune diseases. In Advances in Experimental Medicine and Biology (Vol. 632, pp. 265-272). (Advances in Experimental Medicine and Biology; Vol. 632).

Targeting classical complement pathway to treat complement mediated autoimmune diseases. / Tüzün, Erdem; Li, Jing; Saini, Shamsher S.; Yang, Huan; Christadoss, Premkumar.

Advances in Experimental Medicine and Biology. Vol. 632 2008. p. 265-272 (Advances in Experimental Medicine and Biology; Vol. 632).

Research output: Chapter in Book/Report/Conference proceedingChapter

Tüzün, E, Li, J, Saini, SS, Yang, H & Christadoss, P 2008, Targeting classical complement pathway to treat complement mediated autoimmune diseases. in Advances in Experimental Medicine and Biology. vol. 632, Advances in Experimental Medicine and Biology, vol. 632, pp. 265-272.
Tüzün E, Li J, Saini SS, Yang H, Christadoss P. Targeting classical complement pathway to treat complement mediated autoimmune diseases. In Advances in Experimental Medicine and Biology. Vol. 632. 2008. p. 265-272. (Advances in Experimental Medicine and Biology).
Tüzün, Erdem ; Li, Jing ; Saini, Shamsher S. ; Yang, Huan ; Christadoss, Premkumar. / Targeting classical complement pathway to treat complement mediated autoimmune diseases. Advances in Experimental Medicine and Biology. Vol. 632 2008. pp. 265-272 (Advances in Experimental Medicine and Biology).
@inbook{7c74593af2084b66b7c56650ee9c1379,
title = "Targeting classical complement pathway to treat complement mediated autoimmune diseases",
abstract = "Mice deficient for classical complement pathway (CCP) factor C4 are resistant to antibody and complement mediated experimental autoimmune myasthenia gravis (EAMG). Anti-C1q antibody administration before or following acetylcholine receptor immunization suppresses EAMG development by reducing lymph node cell IL-6 production and neuromuscular junction IgG, C3 and C5b-C9 deposition. This effect is achieved by treating mice with 10 μg of anti-C1q antibody, twice weekly for 4 weeks. Treatment with a higher amount of anti-C1q antibody gives rise to increased serum anti-acetylcholine receptor antibody, immune complex and C3 levels, facilitates kidney C3 and IgG deposits and thus reduces the treatment efficacy. C4 KO and anti-C1q antibody treated mice display normal immune system functions and intact antibody production capacity. Furthermore, CCP inhibition preserves alternative complement pathway activation, which is required for host defense against microorganisms. Therefore, CCP inhibition might constitute a specific treatment approach for not only myasthenia gravis but also other complement mediated autoimmune diseases.",
author = "Erdem T{\"u}z{\"u}n and Jing Li and Saini, {Shamsher S.} and Huan Yang and Premkumar Christadoss",
year = "2008",
language = "English (US)",
isbn = "9780387789514",
volume = "632",
series = "Advances in Experimental Medicine and Biology",
pages = "265--272",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Targeting classical complement pathway to treat complement mediated autoimmune diseases

AU - Tüzün, Erdem

AU - Li, Jing

AU - Saini, Shamsher S.

AU - Yang, Huan

AU - Christadoss, Premkumar

PY - 2008

Y1 - 2008

N2 - Mice deficient for classical complement pathway (CCP) factor C4 are resistant to antibody and complement mediated experimental autoimmune myasthenia gravis (EAMG). Anti-C1q antibody administration before or following acetylcholine receptor immunization suppresses EAMG development by reducing lymph node cell IL-6 production and neuromuscular junction IgG, C3 and C5b-C9 deposition. This effect is achieved by treating mice with 10 μg of anti-C1q antibody, twice weekly for 4 weeks. Treatment with a higher amount of anti-C1q antibody gives rise to increased serum anti-acetylcholine receptor antibody, immune complex and C3 levels, facilitates kidney C3 and IgG deposits and thus reduces the treatment efficacy. C4 KO and anti-C1q antibody treated mice display normal immune system functions and intact antibody production capacity. Furthermore, CCP inhibition preserves alternative complement pathway activation, which is required for host defense against microorganisms. Therefore, CCP inhibition might constitute a specific treatment approach for not only myasthenia gravis but also other complement mediated autoimmune diseases.

AB - Mice deficient for classical complement pathway (CCP) factor C4 are resistant to antibody and complement mediated experimental autoimmune myasthenia gravis (EAMG). Anti-C1q antibody administration before or following acetylcholine receptor immunization suppresses EAMG development by reducing lymph node cell IL-6 production and neuromuscular junction IgG, C3 and C5b-C9 deposition. This effect is achieved by treating mice with 10 μg of anti-C1q antibody, twice weekly for 4 weeks. Treatment with a higher amount of anti-C1q antibody gives rise to increased serum anti-acetylcholine receptor antibody, immune complex and C3 levels, facilitates kidney C3 and IgG deposits and thus reduces the treatment efficacy. C4 KO and anti-C1q antibody treated mice display normal immune system functions and intact antibody production capacity. Furthermore, CCP inhibition preserves alternative complement pathway activation, which is required for host defense against microorganisms. Therefore, CCP inhibition might constitute a specific treatment approach for not only myasthenia gravis but also other complement mediated autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=58149349890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149349890&partnerID=8YFLogxK

M3 - Chapter

C2 - 19025128

AN - SCOPUS:58149349890

SN - 9780387789514

VL - 632

T3 - Advances in Experimental Medicine and Biology

SP - 265

EP - 272

BT - Advances in Experimental Medicine and Biology

ER -